Population cessation of aspirin use for the prevention of cardiovascular disease

IF 4.3 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS American journal of preventive cardiology Pub Date : 2025-03-01 DOI:10.1016/j.ajpc.2025.100941
Stephanea Roeser , Sue Duval , Russell V. Luepker , Milton Eder , John R. Finnegan , Jeremy R. Van't Hof
{"title":"Population cessation of aspirin use for the prevention of cardiovascular disease","authors":"Stephanea Roeser ,&nbsp;Sue Duval ,&nbsp;Russell V. Luepker ,&nbsp;Milton Eder ,&nbsp;John R. Finnegan ,&nbsp;Jeremy R. Van't Hof","doi":"10.1016/j.ajpc.2025.100941","DOIUrl":null,"url":null,"abstract":"<div><h3>Importance</h3><div>Aspirin use for primary prevention of cardiovascular diseases (CVD) is widespread with over a third of the adult population using despite guidelines recommending against.</div></div><div><h3>Objective</h3><div>This population-based research documents rates of use and reasons for cessation from 2015 to 2020, a period when guidelines changed.</div></div><div><h3>Design</h3><div>Three cross-sectional telephone surveys were conducted during 2015, 2017, and 2019–20.</div></div><div><h3>Setting</h3><div>A population-based survey in the states of Iowa, Minnesota, North Dakota, South Dakota, and Wisconsin.</div></div><div><h3>Participants</h3><div>The surveys included non-institutionalized resident adults ages 55–79 for women and 45–79 for men with landline telephones.</div></div><div><h3>Main Outcomes and Measures</h3><div>The analysis included 8,197 participants, 4,161 women and 4,036 men after excluding those with a history of cardiovascular disease (secondary prevention). Aspirin use for primary prevention was stable for the first two survey years (39 % in 2015 and 41 % in 2017) but fell significantly to 34 % in the final survey (2019–2020). The most common reason for cessation was “doctor's advice” (38 % of quitters) followed by “heard negative news” with a significant increase from 2015 to 2020 (4 % to 29 % of quitters).</div></div><div><h3>Conclusions and Relevance</h3><div>Despite recent research findings and new guidelines, aspirin is still widely used for primary prevention of CVD in the general population. A combination of slow diffusion and implementation of guidelines, self-medication, and wide availability of low-cost aspirin underlies these trends. Physician advice is effective but more is needed. The influence of the popular media is also substantial. Appropriate implementation of aspirin guidelines requires additional clinician effort.</div></div><div><h3>Trial Registration</h3><div>Clinicaltrials.gov registered on December 1, 2014, NCT02607917</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100941"},"PeriodicalIF":4.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of preventive cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666667725000145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Importance

Aspirin use for primary prevention of cardiovascular diseases (CVD) is widespread with over a third of the adult population using despite guidelines recommending against.

Objective

This population-based research documents rates of use and reasons for cessation from 2015 to 2020, a period when guidelines changed.

Design

Three cross-sectional telephone surveys were conducted during 2015, 2017, and 2019–20.

Setting

A population-based survey in the states of Iowa, Minnesota, North Dakota, South Dakota, and Wisconsin.

Participants

The surveys included non-institutionalized resident adults ages 55–79 for women and 45–79 for men with landline telephones.

Main Outcomes and Measures

The analysis included 8,197 participants, 4,161 women and 4,036 men after excluding those with a history of cardiovascular disease (secondary prevention). Aspirin use for primary prevention was stable for the first two survey years (39 % in 2015 and 41 % in 2017) but fell significantly to 34 % in the final survey (2019–2020). The most common reason for cessation was “doctor's advice” (38 % of quitters) followed by “heard negative news” with a significant increase from 2015 to 2020 (4 % to 29 % of quitters).

Conclusions and Relevance

Despite recent research findings and new guidelines, aspirin is still widely used for primary prevention of CVD in the general population. A combination of slow diffusion and implementation of guidelines, self-medication, and wide availability of low-cost aspirin underlies these trends. Physician advice is effective but more is needed. The influence of the popular media is also substantial. Appropriate implementation of aspirin guidelines requires additional clinician effort.

Trial Registration

Clinicaltrials.gov registered on December 1, 2014, NCT02607917
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
American journal of preventive cardiology
American journal of preventive cardiology Cardiology and Cardiovascular Medicine
CiteScore
6.60
自引率
0.00%
发文量
0
审稿时长
76 days
期刊最新文献
Population cessation of aspirin use for the prevention of cardiovascular disease Individualized prediction of atrial fibrillation onset risk based on lifelogs Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS) ASPC President's page - Imaging the future of prevention
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1